Intensive Lipid-Lowering Therapy as per the Latest Dyslipidemia Management Guideline in Predicting Favorable

Liang Tang1, Hao Chen1, Xin-Qun Hu1

  • 1Department of Cardiology The Second Xiangya Hospital of Central South University Changsha Hunan China.

Insights

Most patients undergoing coronary artery bypass grafting (CABG) do not achieve their low-density lipoprotein cholesterol (LDL-C) goals one year post-surgery. Poor LDL-C control after CABG is linked to higher risks of major adverse cardiovascular and cerebrovascular events (MACCEs).

Area of Science:

  • Cardiology
  • Vascular Surgery
  • Lipid Metabolism

Background:

  • Limited data exist on low-density lipoprotein cholesterol (LDL-C) goal achievement post-coronary artery bypass grafting (CABG) according to 2019 ESC/EAS guidelines.
  • The impact of LDL-C levels on long-term outcomes in CABG patients remains under-investigated.

Purpose of the Study:

  • To investigate the association between LDL-C levels one year after CABG and long-term patient outcomes.
  • To assess the rate of LDL-C goal attainment in patients post-CABG.

Main Methods:

  • Retrospective analysis of 2072 patients with multivessel coronary artery disease undergoing CABG (2011-2020).
  • Patients categorized by LDL-C levels at 1-year post-CABG.
  • Evaluation of major adverse cardiovascular and cerebrovascular events (MACCEs) during a mean 4.2-year follow-up.

Main Results:

  • Only 14.9% of patients achieved the LDL-C goal (<1.40 mmol/L) at 1 year post-CABG.
  • 25.0% of patients experienced MACCEs during follow-up.
  • Higher LDL-C levels (≥2.60 mmol/L) were independently associated with significantly increased risks of MACCEs, cardiac death, myocardial infarction, and revascularization compared to LDL-C <1.40 mmol/L.

Conclusions:

  • The majority of patients do not achieve lipid goals one year after CABG.
  • Suboptimal LDL-C levels post-CABG are independently associated with increased long-term MACCE risk.
  • Prospective studies are needed to confirm if intensive lipid management improves outcomes in CABG patients.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
681
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
23
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
11